Eric Benevich - 28 Nov 2025 Form 4/A - Amendment Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Commercial Officer
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol: NBIX
Transactions as of: 28 Nov 2025
Net transactions value: +$461,752
Form type: 4/A - Amendment
Filing time: 16 Jan 2026, 17:17:59 UTC
Date Of Original Report: 02 Dec 2025
Previous filing: 02 May 2025
Next filing: 03 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BENEVICH ERIC	Chief Commercial Officer	6027 EDGEWOOD BEND CT., SAN DIEGO	/s/ Darin Lippoldt, Attorney-in-Fact	16 Jan 2026	0001643653

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBIX	Common Stock	Options Exercise	$461,752	+12,830	+29%	$35.99	57,723	28 Nov 2025	Direct	F1, F2
holding	NBIX	Common Stock						51,753	28 Nov 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBIX	Incentive Stock Option	Options Exercise	$0	-12,830	-100%	$0.000000	0	28 Nov 2025	Common Stock	12,830	$35.99	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options.
F2	Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F3	This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025.
F4	The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.